Jefferies Group LLC restated their hold rating on shares of C.R. Bard, Inc. (NYSE:BCR) in a research note released on Thursday morning.

A number of other analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of C.R. Bard from a buy rating to a hold rating in a report on Tuesday, August 1st. BidaskClub downgraded shares of C.R. Bard from a strong-buy rating to a buy rating in a report on Wednesday, July 19th. Finally, BMO Capital Markets reissued a hold rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. C.R. Bard presently has a consensus rating of Hold and a consensus price target of $285.67.

C.R. Bard (BCR) opened at 318.58 on Thursday. The firm has a market cap of $23.15 billion, a price-to-earnings ratio of 41.82 and a beta of 0.59. The company has a 50-day moving average of $317.93 and a 200 day moving average of $279.50. C.R. Bard has a 52-week low of $203.63 and a 52-week high of $323.27.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.84 by $0.08. The firm had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.54 EPS. On average, equities research analysts anticipate that C.R. Bard will post $11.79 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/07/c-r-bard-inc-bcr-receives-hold-rating-from-jefferies-group-llc.html.

The company also recently declared a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were issued a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date of this dividend was Thursday, July 20th. C.R. Bard’s dividend payout ratio (DPR) is presently 13.67%.

Several hedge funds have recently modified their holdings of BCR. Parallel Advisors LLC increased its stake in shares of C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 369 shares during the period. Cribstone Capital Management LLC purchased a new stake in shares of C.R. Bard during the first quarter worth $130,000. Contravisory Investment Management Inc. increased its stake in shares of C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock worth $136,000 after buying an additional 426 shares during the period. Whittier Trust Co. increased its stake in shares of C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock worth $147,000 after buying an additional 42 shares during the period. Finally, ClariVest Asset Management LLC purchased a new stake in shares of C.R. Bard during the first quarter worth $148,000. 86.21% of the stock is owned by institutional investors.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.